LU92041I9 - - Google Patents

Info

Publication number
LU92041I9
LU92041I9 LU92041C LU92041C LU92041I9 LU 92041 I9 LU92041 I9 LU 92041I9 LU 92041 C LU92041 C LU 92041C LU 92041 C LU92041 C LU 92041C LU 92041 I9 LU92041 I9 LU 92041I9
Authority
LU
Luxembourg
Prior art keywords
human
antibodies
disclosed
human antibodies
monoclonal antibodies
Prior art date
Application number
LU92041C
Other languages
English (en)
Other versions
LU92041I2 (fr
Inventor
Paul Parren
Jorgen Petersen
Jessica Woodmill Cottage Teeling
Sigrid Ruuls
Martin Glennie
De Winkel Jan G J Van
Ole D M Sc Baadsgaard
Haichun Huang
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32110219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92041(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab As filed Critical Genmab As
Publication of LU92041I2 publication Critical patent/LU92041I2/fr
Publication of LU92041I9 publication Critical patent/LU92041I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
LU92041C 2002-10-17 2012-07-11 Anticorps monoclonal humain qui se lie au CD20 humain, qui est capable d'induite une cytotoxité dépendente du complément des cellules exprimant CD2, en présence du complément et qui comprend les régions CDR de la chaîne légère et de la chaîne lourde selon EP1558648B1 revendication 1, paragraphes (i),(ii)(a) et (iii)(SEQ ID nos 16,17,18,13,14 et 15) en particulier un anticorps comprenant les séquen ces de la région variable de la chaîne légère et de la chaîne lourde selon EP1558648B1 revendication 4 (SEQ ID nos 4 et 2), en particulier ofatumumab LU92041I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41916302P 2002-10-17 2002-10-17
US46002803P 2003-04-02 2003-04-02
PCT/US2003/033057 WO2004035607A2 (fr) 2002-10-17 2003-10-17 Anticorps monoclonaux humains anti-cd20

Publications (2)

Publication Number Publication Date
LU92041I2 LU92041I2 (fr) 2014-01-11
LU92041I9 true LU92041I9 (fr) 2019-01-03

Family

ID=32110219

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92041C LU92041I2 (fr) 2002-10-17 2012-07-11 Anticorps monoclonal humain qui se lie au CD20 humain, qui est capable d'induite une cytotoxité dépendente du complément des cellules exprimant CD2, en présence du complément et qui comprend les régions CDR de la chaîne légère et de la chaîne lourde selon EP1558648B1 revendication 1, paragraphes (i),(ii)(a) et (iii)(SEQ ID nos 16,17,18,13,14 et 15) en particulier un anticorps comprenant les séquen ces de la région variable de la chaîne légère et de la chaîne lourde selon EP1558648B1 revendication 4 (SEQ ID nos 4 et 2), en particulier ofatumumab

Country Status (25)

Country Link
US (3) US8529902B2 (fr)
EP (4) EP2316856B1 (fr)
JP (3) JP4662473B2 (fr)
KR (7) KR20110140142A (fr)
CN (3) CN1729203B (fr)
AT (1) ATE540978T1 (fr)
AU (1) AU2003301445A1 (fr)
BR (1) BRPI0315295C1 (fr)
CA (2) CA3029035C (fr)
CY (2) CY1112750T1 (fr)
DK (2) DK1558648T3 (fr)
EA (2) EA201492217A1 (fr)
ES (3) ES2744275T3 (fr)
FR (1) FR21C1028I1 (fr)
HK (1) HK1077590A1 (fr)
HU (2) HUE046695T2 (fr)
IL (2) IL167851A (fr)
LT (2) LT3284753T (fr)
LU (1) LU92041I2 (fr)
MX (1) MXPA05004022A (fr)
NZ (2) NZ568769A (fr)
PL (2) PL218660B1 (fr)
PT (2) PT3284753T (fr)
SI (1) SI1558648T1 (fr)
WO (1) WO2004035607A2 (fr)

Families Citing this family (445)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329503T2 (de) * 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE414536T1 (de) * 1998-08-11 2008-12-15 Biogen Idec Inc Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern
EP1949910A1 (fr) 1998-11-09 2008-07-30 Biogen Idec, Inc. Traitement de la léucemie lymphocytaire chronique (CLL) utilisant un anticorps chimérique anti-CD20
JP2002529429A (ja) * 1998-11-09 2002-09-10 アイデック・ファーマシューティカルズ・コーポレイション Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
AU2004252067B2 (en) * 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2004270165A1 (en) * 2003-08-29 2005-03-17 Genentech, Inc. Anti-CD20 therapy of ocular disorders
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
FR2867982B1 (fr) * 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
AR049021A1 (es) * 2004-04-16 2006-06-21 Genentech Inc Tratamiento de trastornos con un anticuerpo que se une a cd20
AU2005244751A1 (en) * 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting B cell depletion
CA2563334A1 (fr) * 2004-04-16 2005-11-17 Genentech, Inc. Dosage pour anticorps
WO2005103081A2 (fr) * 2004-04-20 2005-11-03 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
EP1773393A2 (fr) * 2004-05-05 2007-04-18 Genentech, Inc. Prevention d'une maladie auto-immune
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20150092374A (ko) * 2004-06-04 2015-08-12 제넨테크, 인크. 다발성 경화증의 치료 방법
AU2005259835B2 (en) * 2004-07-02 2011-07-07 The Walter And Eliza Hall Institute Of Medical Research Alpha-helical mimetics
WO2006085967A2 (fr) * 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
EP1776384B1 (fr) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Regions fc de variants
ZA200702335B (en) * 2004-10-05 2009-05-27 Genentech Inc Method for treating vasculitis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
US10206998B2 (en) 2005-01-12 2019-02-19 Proteonova, Inc. Modular targeted therapeutic agents and methods of making same
EP3431503A1 (fr) * 2005-01-12 2019-01-23 Proteonova, Inc. Procédé de fabrication d'agents thérapeutiques ciblés
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
ES2864039T3 (es) 2005-05-20 2021-10-13 Lonza Biologics Plc Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
US20070014720A1 (en) * 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
JP2009501913A (ja) 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP1762575A1 (fr) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharmaceuticals Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
TWI390034B (zh) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
CA2654317A1 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur
WO2008003319A1 (fr) 2006-07-04 2008-01-10 Genmab A/S Molécules de liaison à cd20 pour le traitement de copd
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
CA2665239A1 (fr) 2006-10-02 2008-05-22 Medarex, Inc. Anticorps humains qui se lient au cxcr4, et leurs utilisations
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
ZA200904482B (en) 2007-01-22 2010-09-29 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
EP1970384A1 (fr) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2626372B1 (fr) * 2007-03-29 2018-03-21 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
EP1997832A1 (fr) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
CA3213888A1 (fr) 2007-05-29 2008-12-04 Novartis Ag Nouvelles indications pour une therapie anti-il-1-beta
WO2008145142A1 (fr) 2007-05-31 2008-12-04 Genmab A/S Anticorps igg4 stables
AU2008255350B2 (en) 2007-05-31 2014-07-10 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
MY147651A (en) * 2007-07-31 2012-12-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
WO2009030368A1 (fr) * 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Polythérapie avec des anticorps anti-cd20 de type i et de type ii
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
US20110091473A1 (en) * 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
KR20140015166A (ko) 2007-10-30 2014-02-06 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
US20090169550A1 (en) * 2007-12-21 2009-07-02 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
TWI500624B (zh) * 2008-03-25 2015-09-21 Hoffmann La Roche 具有增進之抗體依賴型細胞毒性之第ii型抗－ｃｄ２０抗體之組合療法
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
US20090269339A1 (en) * 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
WO2010009271A2 (fr) 2008-07-15 2010-01-21 Academia Sinica Matrices de glycane sur des lames de verre revêtues d’aluminium de type ptfe et procédés associés
WO2010014784A2 (fr) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec divers régimes thérapeutiques pour un traitement synergétique de maladies prolifératives
RS59232B1 (sr) 2008-08-14 2019-10-31 Genentech Inc Postupci za uklanjanje zagađivača koristeći hromatografiju membrane razmene jona sa razmeštanjem autohtonih proteina
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
EP2166021A1 (fr) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
CA3053156A1 (fr) 2008-12-03 2010-06-10 Genmab A/S Variants d'anticorps comportant des modifications dans la region constante
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
EP2373339B1 (fr) * 2009-01-06 2017-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Agent de déplétion de lymphocytes B pour le traitement de l'athérosclérose
BRPI1006829A2 (pt) * 2009-01-16 2016-10-25 Glaxosmithkline Llc tratamento de um câncer empregando uma combinação de bendamustina e um anticorpo anti-cd20
FI2398902T3 (fi) 2009-02-20 2023-11-28 Astellas Pharma Inc Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
AR075982A1 (es) * 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
DK2769737T3 (en) 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
JP2013501741A (ja) 2009-08-14 2013-01-17 ロシュ グリクアート アーゲー アフコシル化ｃｄ２０抗体とフルダラビン及び／又はミトキサントロンの併用療法
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
BR112012004777A2 (pt) 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20110070227A1 (en) * 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
EP2496604B1 (fr) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Anticorps contre cd20 canine
EP2322555A1 (fr) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Anticorps spécifiques pour claudin 6 (CLDN6)
KR102126964B1 (ko) 2009-11-11 2020-06-25 가니메드 파마슈티칼스 게엠베하 클라우딘 6 특이적 항체
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
CN105001334A (zh) * 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
TW201129383A (en) * 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
KR101878369B1 (ko) 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
EP2371864A1 (fr) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Anticorps monoclonaux pour le traitement du cancer
WO2011130332A1 (fr) 2010-04-12 2011-10-20 Academia Sinica Puces au glycane pour la recherche par criblage haut débit de virus
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CA2796633C (fr) † 2010-04-23 2020-10-27 Genentech, Inc. Production de proteines heteromultimeres
KR101620661B1 (ko) 2010-04-27 2016-05-12 로슈 글리카트 아게 어푸코실화된 ＣＤ20 항체와 mTOR 억제제의 복합 요법
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
WO2011143262A2 (fr) 2010-05-10 2011-11-17 Sinica, Academia Congénères de phosphonate de zanamivir ayant une activité antigrippale et détermination de la sensibilité à l'oseltamivir d'influenzavirus
WO2011146382A1 (fr) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Régimes posologiques immunothérapeutiques améliorés et combinaisons de ceux-ci
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
EP2600895A1 (fr) 2010-08-03 2013-06-12 Hoffmann-La Roche AG Biomarqueurs de la leucémie lymphoïde chronique (llc)
EP2600901B1 (fr) 2010-08-06 2019-03-27 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
JP2013541594A (ja) 2010-11-08 2013-11-14 ジェネンテック， インコーポレイテッド 皮下投与される抗ｉｌ−６受容体抗体
EP4303236A3 (fr) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique inducteur de cytotoxicité
JP6157045B2 (ja) * 2010-12-06 2017-07-05 公益財団法人がん研究会 Ｃｄ２０認識モノクローナル抗体、ハイブリドーマ、ｃｄ２０の検出方法および判定方法
CA2819436A1 (fr) 2010-12-16 2012-06-21 Roche Glycart Ag Therapie d'association d'un anticorps cd20 afucosyle avec un inhibiteur mdm2
WO2012096924A1 (fr) * 2011-01-10 2012-07-19 Glaxo Group Limited Nouvelles utilisations
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
CA2831613A1 (fr) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Administration et formulation d'acides nucleiques genetiquement modifies
CA2832389A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2 et cd3
CA2832387A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2
DK3026064T3 (en) 2011-05-13 2019-01-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6
BR122016016837A2 (pt) 2011-05-21 2019-08-27 Macrogenics Inc moléculas de ligação a cd3; anticorpos de ligação a cd3; composições farmacêuticas; e usos da molécula de ligação a cd3
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
KR20140061379A (ko) 2011-07-06 2014-05-21 모르포시스 아게 항­ｃｄ20 및 항­ｇｍ­ｃｓｆ 항체의 치료 조합물 및 이의 용도
EP2729496B8 (fr) 2011-07-06 2017-10-18 Genmab A/S Modulation de la cytotoxicité dépendante du complément par des modifications de l'extrémité c-terminale des chaînes lourdes d'anticorps
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN102875678B (zh) * 2011-07-13 2014-08-06 无锡天演生物技术有限公司 全人源抗人cd20单抗分子及其应用
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2014533930A (ja) * 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
EP3492109B1 (fr) 2011-10-03 2020-03-04 ModernaTX, Inc. Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations
WO2013063186A2 (fr) 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Anticorps monoclonaux et leurs procédés d'utilisation
EP3674320A3 (fr) 2011-10-27 2020-08-12 Genmab A/S Production de proteines heterodimeres
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
JP6605202B2 (ja) 2011-12-22 2019-11-13 ジェネンテック， インコーポレイテッド イオン交換膜クロマトグラフィー
BR112014018471A2 (pt) 2012-01-31 2017-07-04 Genentech Inc anticorpos anti-ige m1' e métodos para o seu uso
CN102585000B (zh) * 2012-02-22 2013-05-29 尉军 一种肿瘤标志物cd25自身抗体及应用
WO2013138702A2 (fr) 2012-03-15 2013-09-19 Bristol-Myers Squibb Company Méthodes de prévision des événements indésirables gastro-intestinaux immunitaires chez les patients traités par modulation de la voie de co‑stimulation
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
PL2662386T3 (pl) 2012-05-07 2019-08-30 Astellas Pharma Inc. Przeciwciała, które wiążą się z PLAC1 i blokują interakcję między PLAC1 a FGF7
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013169971A1 (fr) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anticorps antitumoraux à titre de biomarqueurs prédictifs ou pronostiques de l'efficacité et de la survie chez les patients traités à l'ipilimumab
CA2873646C (fr) 2012-05-18 2022-04-26 Genentech, Inc. Formulations d'anticorps monoclonal a concentration elevee
WO2013174403A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
EP3725810B1 (fr) 2012-05-23 2022-07-06 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 pour le traitement du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
EP4364756A3 (fr) 2012-05-23 2024-07-31 Astellas Pharma Inc. Polythérapie impliquant des anticorps contre la claudine 18.2 pour le traitement du cancer
EP3632462A1 (fr) 2012-07-06 2020-04-08 Genmab B.V. Protéine dimérique ayant des mutations triples
DK2869845T3 (da) * 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
CN103588882B (zh) * 2012-08-13 2015-10-28 中国抗体制药有限公司 针对人cd22抗体的抗独特型抗体及其应用
WO2014031498A1 (fr) 2012-08-18 2014-02-27 Academia Sinica Sondes perméables aux cellules pour l'identification et l'imagerie de sialidases
WO2014031762A1 (fr) 2012-08-21 2014-02-27 Academia Sinica Composés benzocyclo-octyne et leurs utilisations
US8643360B1 (en) * 2012-09-02 2014-02-04 George S. Cargill, III In-water voltage gradient detector
KR102158467B1 (ko) 2012-09-07 2020-09-25 제넨테크, 인크. Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
AU2013337926B2 (en) 2012-10-30 2017-12-21 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
WO2014075697A1 (fr) 2012-11-13 2014-05-22 Biontech Ag Agents de traitement de maladies cancéreuses exprimant claudine
BR122020024124B1 (pt) 2012-11-13 2024-01-30 Biontech Ag Agentes para tratamento de doenças cancerosas expressando claudina
CA2890438C (fr) * 2012-11-13 2022-10-18 Biontech Ag Agents de traitement de maladies cancereuses exprimant claudine
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
CN103173412B (zh) * 2012-12-07 2015-04-22 天津三箭生物技术有限公司 小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
WO2014108198A1 (fr) 2013-01-10 2014-07-17 Genmab B.V. Variantes de la région fc d'igg1 humaine et leurs utilisations
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
EP4177273A1 (fr) 2013-02-20 2023-05-10 Astellas Pharma Inc. Polythérapie impliquant des anticorps contre la claudine 18.2 pour le traitement du cancer
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
AU2014243783B2 (en) 2013-03-13 2018-12-13 Genentech, Inc. Antibody formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
SI2976360T1 (sl) 2013-03-18 2020-04-30 Astellas Pharma Inc. Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
WO2014169078A2 (fr) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Procédés de traitement du cancer
EP2986312B1 (fr) 2013-04-19 2021-12-15 Cytune Pharma Traitement dérivé de la cytokine avec syndrome de fuite vasculaire réduit
CN103254317B (zh) * 2013-05-08 2014-08-13 浙江大学 一种抗cd20单克隆抗体-海兔毒素偶联物及其制备方法和应用
EP3013365B1 (fr) 2013-06-26 2019-06-05 Academia Sinica Antigènes rm2 et leur utilisation
EP3013347B1 (fr) 2013-06-27 2019-12-11 Academia Sinica Conjugués de glycane et leur utilisation
CN113248615A (zh) 2013-07-05 2021-08-13 根马布股份公司 人源化或嵌合cd3抗体
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
EP3738611A1 (fr) 2013-07-31 2020-11-18 BioNTech AG Diagnostic et traitement du cancer impliquant des cellules souches cancéreuses
EP4269441A3 (fr) 2013-08-08 2024-01-24 Cytune Pharma Domaine sushi de l'il-15 et de l'il-15ralpha basé sur des modulokines
CA2920539C (fr) 2013-08-08 2024-01-02 Cytune Pharma Composition pharmaceutique combinee
CN103467605B (zh) * 2013-09-05 2015-02-04 武汉友芝友生物制药有限公司 一种cd3抗原及其制备方法和用途
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
BR112016010224A2 (pt) 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
US20160264670A1 (en) 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
NZ718792A (en) * 2013-11-07 2020-05-29 Hoffmann La Roche Combination therapy of an anti cd20 antibody with a btk inhibitor
CN106414494B (zh) 2013-11-12 2020-09-18 Ogd2药物 具有促凋亡活性的人IgG1衍生的抗体
RU2016128726A (ru) 2013-12-17 2018-01-23 Дженентек, Инк. Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20
WO2015109180A2 (fr) 2014-01-16 2015-07-23 Academia Sinica Compositions et méthodes pour traiter et détecter des cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP2910645A1 (fr) 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Procédés et compositions pour la prédiction de l'efficacité thérapeutique de traitements du cancer et le pronostic du cancer lors d'un traitement à base d'anticorps
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
CN103880958B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l4h6及其应用
CN103880957B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l1h1及其应用
CA2943943C (fr) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Molecule d'immunoactivation de liaison a un antigene
EP3909602A1 (fr) 2014-04-25 2021-11-17 University of Florida Research Foundation, Inc. Méthodes permettant qu'un sujet reçoive des doses multiples de virus adéno-associé recombinant
CN106471117A (zh) 2014-05-06 2017-03-01 豪夫迈·罗氏有限公司 使用哺乳动物细胞产生异多聚体蛋白
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
CA2950415A1 (fr) 2014-05-27 2015-12-03 Academia Sinica Glycoanticorps anti-cd20 et leurs utilisations
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
JP6899321B2 (ja) 2014-09-08 2021-07-07 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 糖脂質を使用するヒトｉＮＫＴ細胞活性化
WO2016044334A1 (fr) 2014-09-15 2016-03-24 Genentech, Inc. Formulations d'anticorps
EP3689910A3 (fr) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Procédé d'utilisation d'immunoconjugués anti-cd79b
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN115040532A (zh) 2014-10-10 2022-09-13 伊黛拉制药有限公司 使用tlr9激动剂与检查点抑制剂对癌症的治疗
EP3699198A1 (fr) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Procédés pour le traitement de tumeurs à l'aide d'anticorps bispécifiques cd3xcd20
JP2017537927A (ja) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
WO2016100232A1 (fr) 2014-12-15 2016-06-23 The Regents Of The University Of California Récepteur d'antigène chimère de type porte ou bispécifique sensible à cd19 et à cd20
EP3233907B1 (fr) 2014-12-19 2021-03-03 Genmab A/S Protéines hétérodimères bispécifiques de rongeurs
JP6853176B2 (ja) * 2015-01-08 2021-03-31 ゲンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
CN107428818A (zh) 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
BR112017018941B8 (pt) * 2015-03-04 2023-01-10 Igm Biosciences Inc Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20
WO2016146143A1 (fr) 2015-03-16 2016-09-22 Amal Therapeutics Sa Peptides pénétrant dans les cellules et complexes comprenant ceux-ci
EP3273974A4 (fr) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Thérapie pour une affection maligne
WO2016165762A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Conjugués de médicaments comprenant des anticorps contre la claudine 18.2
WO2016165765A1 (fr) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Procédés et compositions permettant de prédire l'efficacité thérapeutique des traitements contre le cancer et de pronostiquer un cancer
CN107529739B (zh) * 2015-04-30 2021-01-08 株式会社特殊免疫研究所 表达人特定分子和人Fcγ受体家族的转基因非人动物
US20180104331A1 (en) 2015-05-11 2018-04-19 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
EP3936524A3 (fr) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Compositions et procédés de traitement du lupus nephritis
EP3297672B1 (fr) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Protéines trispécifiques de liaison et méthodes d'utilisation
AU2016267059B2 (en) 2015-05-22 2020-08-13 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
EA201792623A1 (ru) 2015-06-03 2018-04-30 Бостон Биомедикал, Инк. Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
EP3108897A1 (fr) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Anticorps contre le csf-1r humain permettant d'induire une lymphocytose dans les lymphomes ou les leucémies
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
PT3313528T (pt) 2015-06-29 2021-09-16 Bristol Myers Squibb Co Regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do cancro
JP2018520153A (ja) 2015-06-29 2018-07-26 ジェネンテック， インコーポレイテッド 臓器移植における使用のためのｉｉ型抗ｃｄ２０抗体
WO2017005649A1 (fr) 2015-07-09 2017-01-12 Genmab A/S Anticorps bispécifiques et multispécifiques et procédé pour l'isolement de ceux-ci
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
EP3328896A4 (fr) 2015-07-31 2019-08-07 University of Florida Research Foundation, Inc. Cellules souches hématopoïétiques en thérapie combinatoire comprenant des inhibiteurs de points de contrôle immunitaires contre le cancer
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
EP3334747B1 (fr) 2015-08-13 2023-09-27 Amgen Inc. Filtration en profondeur chargée de protéines de liaison à un antigène
EP3352760A4 (fr) 2015-09-21 2019-03-06 Aptevo Research and Development LLC Polypeptides de liaison à cd3
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
CN107531793B (zh) * 2015-10-13 2022-01-11 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
EP3178848A1 (fr) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Anticorps de type ii contre cd20 pour la reduction de la formation des anticorps contre des médicaments
CN105348388B (zh) * 2015-12-11 2018-10-19 安徽大学 抗cd20抗原的抗体l3h3及其应用
WO2017115773A1 (fr) 2015-12-28 2017-07-06 中外製薬株式会社 Procédé pour favoriser l'efficacité de purification d'un polypeptide contenant une région fc
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
JP2019517991A (ja) 2016-03-01 2019-06-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 低減したａｄｃｐを有するオビヌツズマブ及びリツキシマブ変異体
EP3423593A1 (fr) 2016-03-02 2019-01-09 Institut National de la Sante et de la Recherche Medicale (INSERM) Procédés et kits de prédiction du risque de rechute chez des patients souffrant d'un syndrome néphrotique idiopathique
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
WO2017160599A1 (fr) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'antagonistes de cd300b pour traiter un sepsis et un choc septique
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
EP3429693B1 (fr) 2016-03-15 2023-08-23 Mersana Therapeutics, Inc. Conjugués anticorps-médicament ciblant napi2b et leurs procédés d'utilisation
AU2017234192B2 (en) 2016-03-16 2024-04-04 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
EP3445378A1 (fr) 2016-04-22 2019-02-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions vaccinales pour le traitement des malignités des cellules b
US20190298824A1 (en) 2016-05-04 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Albumin-binding immunomodulatory compositions and methods of use thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN109641044A (zh) 2016-05-30 2019-04-16 吉奥瓦科斯公司 用于产生对乙型肝炎病毒的免疫应答的组合物和方法
EP3252078A1 (fr) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
UA124734C2 (uk) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Антитіло проти с5 і його застосування
EP3472614A1 (fr) * 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG Dosage et procédé de détermination d'anticorps induisant la cdc
KR20190035714A (ko) 2016-06-30 2019-04-03 온코루스, 인크. 치료 폴리펩티드의 위형된 종양용해성 바이러스 전달
CN106267406B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病血液净化器
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
EP3500594A4 (fr) 2016-08-22 2020-03-11 Cho Pharma Inc. Anticorps, fragments de liaison, et procédés d'utilisation
WO2018044172A1 (fr) * 2016-09-01 2018-03-08 Umc Utrecht Holding B.V. Anticorps anti-cd20
KR20230131498A (ko) 2016-09-21 2023-09-13 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
WO2018054484A1 (fr) 2016-09-23 2018-03-29 Biontech Ag Anticorps trivalents bispécifiques se liant à claudine 6 ou claudin18.2 et cd3 pour le traitement de maladies cancéreuses exprimant la claudine
BR112019008702A2 (pt) 2016-11-01 2019-07-16 Genmab B.V. polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3544601B1 (fr) 2016-11-23 2024-03-20 Translational Drug Development, LLC Composition comprenant un benzamide et un agoniste du tnfrsf se liant à 4-1bb ou gitr, et son utilisation dans le traitement du cancer.
BR112019010878A2 (pt) 2016-11-29 2019-10-01 Lindhofer Horst combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US20200003785A1 (en) 2016-12-01 2020-01-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
KR20190090822A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 요법
AU2017369994A1 (en) 2016-12-01 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
EP4252629A3 (fr) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
EP3554542A1 (fr) 2016-12-19 2019-10-23 H. Hoffnabb-La Roche Ag Polythérapie avec des agonistes de 4-1bb (cd137) ciblés
PL3559034T3 (pl) 2016-12-20 2021-04-19 F. Hoffmann-La Roche Ag Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
WO2018148381A1 (fr) 2017-02-07 2018-08-16 Nantcell, Inc. Maximisation de la mémoire de cellules t, compositions et méthodes associées
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
SG11201906961UA (en) 2017-02-10 2019-08-27 Genmab Bv Polypeptide variants and uses thereof
WO2018160538A1 (fr) 2017-02-28 2018-09-07 Mersana Therapeutics, Inc. Polythérapies de conjugués anticorps-médicament ciblant her2
WO2018167780A1 (fr) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Méthodes de diagnostic et de traitement du cancer
US20200150125A1 (en) 2017-03-12 2020-05-14 Yeda Research And Development Co., Ltd. Methods of diagnosing and prognosing cancer
EP4108183A1 (fr) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
NZ757603A (en) 2017-03-31 2024-05-31 Genmab Holding B V Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
CA3063359A1 (fr) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Proteines de liaison a la mesotheline
CA3062656A1 (fr) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methodes pour le traitement du cancer
EP3634584B1 (fr) 2017-06-09 2024-09-18 Providence Health & Services - Oregon Cellules t infiltrant les tumeurs pour le traitement du cancer
CN107446046A (zh) * 2017-07-05 2017-12-08 无锡傲锐东源生物科技有限公司 抗cd20蛋白单克隆抗体及其用途
EP3658584A1 (fr) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
WO2019048040A1 (fr) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh Anticorps utiles dans le diagnostic du cancer
JP7066837B2 (ja) 2017-10-13 2022-05-13 ハープーン セラピューティクス，インク． Ｂ細胞成熟抗原結合タンパク質
WO2019077123A1 (fr) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits pour identifier si un sujet est atteint ou risque d'être atteint d'une myopathie auto-immune
WO2019104289A1 (fr) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Conjugués anticorps-pyrrolobenzodiazépine
WO2019115659A1 (fr) 2017-12-14 2019-06-20 F. Hoffmann-La Roche Ag Utilisation d'un anticorps bispécifique anti-cea/anti-cd3 et d'un antagoniste de liaison à l'axe pd-1 dans un régime posologique pour traiter le cancer
TW201929908A (zh) 2017-12-21 2019-08-01 美商梅爾莎納醫療公司 吡咯并苯并二氮呯抗體共軛物
WO2019133847A1 (fr) 2017-12-29 2019-07-04 Oncorus, Inc. Administration par un virus oncolytique de polypeptides thérapeutiques
WO2019145455A1 (fr) 2018-01-24 2019-08-01 Genmab B.V. Variants polypeptidiques et leurs utilisations
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
CA3093742A1 (fr) 2018-03-12 2019-09-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Utilisation de mimetiques de restriction calorique pour potentialiser la chimio-immunotherapie pour le traitement de cancers
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
MX2020009468A (es) 2018-03-13 2020-10-22 Hoffmann La Roche Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
AU2019285344A1 (en) 2018-06-15 2020-12-10 Mina Therapeutics Limited Combination therapies comprising C/EBP alpha saRNA
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019243636A1 (fr) 2018-06-22 2019-12-26 Genmab Holding B.V. Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
EP3810649A1 (fr) 2018-06-22 2021-04-28 Genmab A/S Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents
CA3105947A1 (fr) * 2018-07-09 2020-01-16 Millennium Pharmaceuticals, Inc. Administration d'inhibiteur d'enzyme d'activation sumo et anticorps anti-cd20
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
EP3833762A4 (fr) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Compositions oligonucléotidiques pour cibler ccr2 et csf1r et leurs utilisations
CA3110513A1 (fr) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Strategie de dosage permettant d'attenuer le syndrome de liberation de cytokines pour des anticorps bispecifiques cd3/c20
WO2020048942A1 (fr) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques visant à améliorer les réponses immunitaires dépendantes des lymphocytes t cytotoxiques
CN112955172A (zh) 2018-09-17 2021-06-11 美国卫生和人力服务部 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
WO2020058372A1 (fr) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et composition pharmaceutique pour le traitement du cancer résistant à une thérapie ciblant des points de contrôle immunitaires
WO2020069028A1 (fr) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Protéines de liaison à dll3 et méthodes d'utilisation
US20220040183A1 (en) 2018-10-01 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
US20240252635A1 (en) 2018-10-04 2024-08-01 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
EP3868784A4 (fr) 2018-10-15 2022-07-27 Industry-Academic Cooperation Foundation, Yonsei University Anticorps à productivité améliorée et procédé de production correspondant
US20210388106A1 (en) * 2018-10-26 2021-12-16 Teneobio, Inc. Heavy chain antibodies binding to cd38
EP3873534A1 (fr) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Conjugués anticorps-médicament modifiés par une cystéine avec des lieurs contenant des peptides
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
MX2021005808A (es) 2018-11-20 2021-07-02 Univ Cornell Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
ES2971964T3 (es) 2018-11-28 2024-06-10 Inst Nat Sante Rech Med Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
WO2020115262A1 (fr) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de cd26 et cd39 en tant que nouveaux marqueurs phénotypiques pour évaluer la maturation de lymphocytes t ffoxp3+ et leurs utilisations à des fins de diagnostic
MA54448A (fr) 2018-12-11 2021-10-20 Theravance Biopharma R&D Ip Llc Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
WO2020127059A1 (fr) 2018-12-17 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de sulconazole en tant qu'inhibiteur de la furine
SG11202107606VA (en) 2019-01-15 2021-08-30 Inst Nat Sante Rech Med Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
WO2020169472A2 (fr) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'induction de changements phénotypiques dans des macrophages
CA3133652A1 (fr) 2019-04-01 2020-10-08 Genentech, Inc. Compositions et procedes de stabilisation de formulations contenant des proteines
JP2022527972A (ja) 2019-04-02 2022-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 前悪性病変を有する患者において癌を予測及び予防する方法
WO2020208060A1 (fr) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de sk2 en association avec une thérapie de blocage de point de contrôle immunitaire pour le traitement du cancer
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
AU2020275415A1 (en) 2019-05-14 2021-11-25 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
CN110551221B (zh) 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
MX2021015433A (es) 2019-07-02 2022-06-08 Hutchinson Fred Cancer Res Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas.
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
WO2021041678A1 (fr) * 2019-08-30 2021-03-04 Qilu Puget Sound Biotherapeutics Corporation Anticorps anti-cd20, anticorps anti-cd37 et leurs mélanges
CA3152192A1 (fr) 2019-09-11 2021-03-18 Novartis Ag Gestion d'etats autres que la sclerose en plaques chez des patients traites par l'ofatumumab
EP4230655A3 (fr) 2019-09-11 2023-11-01 Novartis AG Traitement de rms par thérapie par commutation
TW202118512A (zh) 2019-09-12 2021-05-16 美商建南德克公司 治療狼瘡性腎炎之組成物及方法
WO2021058091A1 (fr) 2019-09-24 2021-04-01 Biontech Rna Pharmaceuticals Gmbh Traitement impliquant un anticorps thérapeutique et l'interleukine-2 (il2)
EP3800201A1 (fr) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Stimulation cd28h améliorant des activités de destruction de cellules nk
EP4037710A1 (fr) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes et composition pharmaceutique pour le traitement du cancer de l'ovaire, du cancer du sein ou du cancer du pancréas
MX2022004443A (es) 2019-10-18 2022-05-02 Genentech Inc Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
EP4055046A1 (fr) 2019-11-06 2022-09-14 Genmab B.V. Combinaisons de variants d'anticorps et leurs utilisations
CN114728941A (zh) 2019-11-22 2022-07-08 施万生物制药研发Ip有限责任公司 作为alk5抑制剂的经取代的1,5-萘啶或喹啉
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023507120A (ja) * 2019-12-18 2023-02-21 テネオフォー， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
JP2023514692A (ja) 2020-02-21 2023-04-07 ジェンマブ ビー．ブイ． 糖蛋白質の定量のための方法
EP4126824A1 (fr) 2020-03-31 2023-02-08 Theravance Biopharma R&D IP, LLC Pyrimidines substituées et méthodes d'utilisation
KR20220166827A (ko) 2020-04-09 2022-12-19 노파르티스 아게 혈청 IgG를 유지하면서 MS를 치료하기 위한 오파투무맙
CA3175499A1 (fr) 2020-04-21 2021-10-28 University Of Rochester Inhibiteurs de la proteine epididymus humaine 4
CA3176356A1 (fr) 2020-04-22 2021-10-28 Anne BROOKS Systemes et procedes pour coordonner la fabrication de cellules pour l'immunotherapie specifique au patient
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
BR112022022730A2 (pt) 2020-05-08 2023-02-14 Genmab As Método para tratar um linfoma não hodgkin de células b em um indivíduo humano
WO2021245071A1 (fr) 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combinaison d'une enzyme hydrolysant l'atp et d'un modulateur de point de contrôle immunitaire et ses utilisations
US20210387983A1 (en) 2020-06-10 2021-12-16 Theravance Biopharma R&D Ip, Llc Crystalline alk5 inhibitors and uses thereof
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
CA3184940A1 (fr) 2020-07-07 2022-01-13 Jennifer Donglan WU Anticorps mic et agents de liaison et leurs procedes d'utilisation
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
US20230295146A1 (en) 2020-07-24 2023-09-21 The University Of Rochester Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
WO2022043415A1 (fr) 2020-08-27 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de détection de la présence d'auto-anticorps spécifiques à un pemphigus dans un échantillon
AU2021341509A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
IL301085A (en) 2020-09-10 2023-05-01 Genmab As A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
AU2021339006A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
MX2023002540A (es) 2020-09-10 2023-03-14 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular.
EP4210745A1 (fr) 2020-09-10 2023-07-19 Genmab A/S Anticorps bispécifique anti-cd3 et anti-cd20 en polythérapie pour traiter un lymphome diffus à grandes cellules b
CN116547305A (zh) 2020-11-11 2023-08-04 生物技术公司 针对程序性死亡-1蛋白的单克隆抗体及其在医学中的用途
WO2022130206A1 (fr) 2020-12-16 2022-06-23 Pfizer Inc. POLYTHÉRAPIES À INHIBITEURS DE TGFβR1
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
KR20230117406A (ko) 2021-01-06 2023-08-08 에프. 호프만-라 로슈 아게 Pd1-lag3 이중특이성 항체와 cd20 t 세포 이중특이성항체를 이용한 조합 요법
MX2023010812A (es) 2021-03-15 2023-09-27 Genentech Inc Composiciones y metodos para tratar la nefritis lupica.
AU2022241765A1 (en) 2021-03-24 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
US20240190991A1 (en) 2021-03-26 2024-06-13 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
CN117529336A (zh) 2021-04-14 2024-02-06 诺华股份有限公司 用于治疗亚洲患者的多发性硬化症的奥法木单抗
CA3216459A1 (fr) 2021-04-23 2022-10-27 Profoundbio Us Co. Anticorps anti-cd70, leurs conjugues et leurs procedes d'utilisation
WO2022229644A1 (fr) 2021-04-28 2022-11-03 Mina Therapeutics Limited POLYTHÉRAPIES COMPRENANT C/EBPα ARNSA
JP2024509664A (ja) 2021-04-30 2024-03-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による治療のための投薬
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024518410A (ja) 2021-05-07 2024-05-01 ビエラ バイオ インコーポレイテッド 重症筋無力症を治療するための抗ｃｄ１９抗体の使用
IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
WO2022251359A1 (fr) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Inhibiteurs bicycliques de l'alk5 et procédés d'utilisation
WO2022253756A1 (fr) 2021-06-01 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'agents de déplétion de lymphocytes b pour le traitement d'une cardiopathie rhumatismale
CA3218590A1 (fr) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1 et icos exprimant des lymphocytes t cd4 reactifs aux tumeurs et leur utilisation
WO2022262959A1 (fr) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Agents de liaison bispécifiques se liant à cldn18.2 et cd3
CN117580862A (zh) 2021-06-17 2024-02-20 葛兰素史克知识产权有限公司 用于治疗长新冠和/或SARS-CoV-2感染后急性后遗症(PASC)的方法的抗BAFF抗体
WO2023280790A1 (fr) 2021-07-05 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Signatures génétiques pour prédire la durée de survie chez les patients souffrant d'un carcinome des cellules rénales
KR20240046323A (ko) 2021-07-13 2024-04-08 비온테크 에스이 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
JP2024531314A (ja) 2021-08-16 2024-08-29 ノバルティス アーゲー 小児ｍｓを治療するためのオファツムマブ
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023092099A1 (fr) 2021-11-19 2023-05-25 Ardeagen Corporation Agents de liaison de gpc3, leurs conjugués et leurs procédés d'utilisation
AU2023213099A1 (en) 2022-01-28 2024-07-18 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL314344A (en) 2022-01-28 2024-09-01 Genmab As Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
WO2023180353A1 (fr) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Traitement combiné associant un anticorps bispécifique anti-cd20/anti-cd3 et une chimiothérapie
WO2023198839A2 (fr) 2022-04-13 2023-10-19 Genmab A/S Anticorps bispécifiques dirigés contre cd3 et cd20
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
WO2023201369A1 (fr) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Processus d'expansion de til utilisant des combinaisons spécifiques de cytokine et/ou traitement akti
WO2023217987A1 (fr) 2022-05-12 2023-11-16 BioNTech SE Anticorps monoclonaux dirigés contre la protéine de mort programmée 1 et leur utilisation en médecine
CN116162153B (zh) * 2022-09-01 2024-09-10 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用
WO2024052356A1 (fr) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer
WO2024094822A1 (fr) 2022-11-02 2024-05-10 Genmab A/S Anticorps bispécifiques dirigés contre cd3 et cd20 pour le traitement du syndrome de richter
WO2024094741A1 (fr) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Polythérapie avec un anticorps bispécifique anti-cd19/anti-cd28
WO2024102734A1 (fr) 2022-11-08 2024-05-16 Genentech, Inc. Compositions et méthodes de traitement du syndrome néphrotique idiopathique de l'enfant
WO2024112571A2 (fr) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Procédés bidimensionnels pour l'expansion de lymphocytes infiltrant les tumeurs et thérapies associées
WO2024126457A1 (fr) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et des inhibiteurs de point de contrôle immunitaire
WO2024153636A1 (fr) 2023-01-17 2024-07-25 Institut National de la Santé et de la Recherche Médicale Vasorine en tant que biomarqueur et biocible en néphrologie
WO2024173607A2 (fr) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combinaison d'anticorps bispécifiques et de lymphocytes t récepteurs d'antigènes chimériques destinés au traitement
US20240285762A1 (en) 2023-02-28 2024-08-29 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6218525B1 (en) * 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993001227A1 (fr) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
SK285960B6 (sk) 1991-07-25 2007-12-06 Biogen Idec Inc. Rekombinantné protilátky na liečenie ľudí
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
JP2000516594A (ja) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション 免疫細胞介在全身性疾患の改良された治療法
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
EP1015616A2 (fr) 1997-09-19 2000-07-05 Dana Farber Cancer Institute, Inc. Regulation a mediation intracorps de reactions immunitaires.
JP2003517265A (ja) 1997-12-24 2003-05-27 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血管内皮増殖因子ｄを発現する発現ベクターおよび細胞系、およびメラノーマを治療する方法
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU5097099A (en) 1998-07-16 2000-02-07 Vincent Marinkovich Methods and compositions for cancer treatment
ATE414536T1 (de) * 1998-08-11 2008-12-15 Biogen Idec Inc Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
JP2002529429A (ja) 1998-11-09 2002-09-10 アイデック・ファーマシューティカルズ・コーポレイション Ｂｍｔまたはｐｂｓｃ移植を受ける患者のキメラ化抗ｃｄ２０抗体による治療。
EP1949910A1 (fr) * 1998-11-09 2008-07-30 Biogen Idec, Inc. Traitement de la léucemie lymphocytaire chronique (CLL) utilisant un anticorps chimérique anti-CD20
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
EP1194167B1 (fr) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
CA2379274A1 (fr) 1999-07-12 2001-01-18 Genentech, Inc. Blocage d'une reponse immunitaire a un antigene etranger au moyen d'un antagoniste de liaison a cd20
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
JP2003513012A (ja) 1999-08-11 2003-04-08 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP3214175A1 (fr) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Anticorps ctla-4 humains et leurs utilisations
WO2001034194A1 (fr) * 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Traitement de tumeurs malignes des cellules b a l'aide d'anticorps anti-cd40l associes a des anticorps anti-cd20, et/ou chimiotherapie et radiotherapie
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
ATE373719T1 (de) 2000-02-03 2007-10-15 Millennium Pharm Inc Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EP1125905A1 (fr) 2000-02-16 2001-08-22 Pepscan Systems B.V. Synthèse de segments
AU2001247737A1 (en) * 2000-03-24 2001-10-08 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
MXPA02009523A (es) * 2000-03-30 2003-02-12 Amgen Inc Moleculas similares a cd20/receptor de ige y usos de las mismas.
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
WO2001080884A1 (fr) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
EP2052742A1 (fr) 2000-06-20 2009-04-29 Biogen Idec Inc. Traitement de maladies liées aux lymphocytes B telles des tumeurs et des maladies auto-immunes utilisant une combinaison d'anticorps anti-CD20 froid et d'anticorps anti-CD22 radiomarqué
WO2001097843A2 (fr) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Procedes d'amelioration de la lyse cellulaire provoquee par des anticorps et procedes de traitement du cancer
JP2004502742A (ja) 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
WO2002007783A2 (fr) 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Immunotoxines radiomarquees
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
WO2002022212A2 (fr) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
WO2002034790A1 (fr) 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Igg3 rituxan r variant et utilisations therapeutiques
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2444661A1 (fr) 2001-01-31 2002-08-08 Idec Pharmaceutical Corporation Utilisation d'antagonistes cd23 dans le traitement des troubles neoplasiques
WO2002060485A2 (fr) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Anticorps immunoregulateurs et ses utilisations
EP1383800A4 (fr) 2001-04-02 2004-09-22 Idec Pharma Corp Anticorps recombinants co-exprimes avec gntiii
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
US20090169550A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients

Also Published As

Publication number Publication date
LTC3284753I2 (fr) 2022-09-12
WO2004035607A8 (fr) 2004-06-17
CY2012019I2 (el) 2015-08-05
HK1077590A1 (en) 2006-02-17
CN1729203B (zh) 2014-02-19
JP2012005485A (ja) 2012-01-12
PT3284753T (pt) 2020-05-04
WO2004035607A2 (fr) 2004-04-29
NZ568769A (en) 2010-04-30
ES2744275T3 (es) 2020-02-24
DK3284753T3 (da) 2021-07-05
CY2012019I1 (el) 2015-08-05
EP3284753B1 (fr) 2019-06-05
IL221193A0 (en) 2012-09-24
DK1558648T3 (da) 2012-04-23
PL216630B1 (pl) 2014-04-30
PT1558648E (pt) 2012-04-23
CN101928344B (zh) 2014-08-13
KR20110017020A (ko) 2011-02-18
KR20090088973A (ko) 2009-08-20
KR20110140142A (ko) 2011-12-30
PL402418A1 (pl) 2013-05-27
EP1558648A2 (fr) 2005-08-03
JP2010042002A (ja) 2010-02-25
US20200317799A1 (en) 2020-10-08
BRPI0315295B1 (pt) 2018-12-26
US20040167319A1 (en) 2004-08-26
BR0315295A (pt) 2005-08-30
EP2316856B1 (fr) 2017-08-09
ATE540978T1 (de) 2012-01-15
CA3029035A1 (fr) 2004-04-29
EP2316856A1 (fr) 2011-05-04
LT3284753T (lt) 2020-06-10
PL218660B1 (pl) 2015-01-30
JP4662473B2 (ja) 2011-03-30
KR100944575B1 (ko) 2010-02-25
CN103709250A (zh) 2014-04-09
EA021644B1 (ru) 2015-08-31
EA201492217A1 (ru) 2015-06-30
CY1112750T1 (el) 2015-08-05
ES2524694T3 (es) 2014-12-11
JP5155968B2 (ja) 2013-03-06
KR20100050587A (ko) 2010-05-13
US20140093454A1 (en) 2014-04-03
CN101928344A (zh) 2010-12-29
HUS2100026I1 (hu) 2021-07-28
CA3029035C (fr) 2023-03-07
US8529902B2 (en) 2013-09-10
CA2502552C (fr) 2019-02-12
HUE046695T2 (hu) 2020-03-30
BRPI0315295B8 (pt) 2019-08-20
KR20050049552A (ko) 2005-05-25
CA2502552A1 (fr) 2004-04-29
EP3284753A3 (fr) 2018-03-14
KR101348472B1 (ko) 2014-01-07
JP5767041B2 (ja) 2015-08-19
WO2004035607A3 (fr) 2004-08-12
IL167851A (en) 2013-12-31
EP3284753A2 (fr) 2018-02-21
SI1558648T1 (sl) 2012-05-31
EP2330130A1 (fr) 2011-06-08
EP1558648A4 (fr) 2006-02-15
ES2380621T3 (es) 2012-05-16
LU92041I2 (fr) 2014-01-11
PL376351A1 (en) 2005-12-27
EP1558648B1 (fr) 2012-01-11
KR20120128151A (ko) 2012-11-26
KR100932340B1 (ko) 2009-12-16
NZ581541A (en) 2011-07-29
CN103709250B (zh) 2016-08-10
EA200500679A1 (ru) 2006-02-24
KR20080090565A (ko) 2008-10-08
BRPI0315295C1 (pt) 2021-05-25
EP2330130B1 (fr) 2014-08-27
AU2003301445A1 (en) 2004-05-04
JP2006507844A (ja) 2006-03-09
LTPA2021514I1 (fr) 2021-07-26
MXPA05004022A (es) 2005-10-05
FR21C1028I1 (fr) 2021-08-27
CN1729203A (zh) 2006-02-01
IL167851A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
LTC3284753I2 (fr)
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
AU2003303237A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
HK1082749A1 (en) Human monoclonal antibodies against interleukin 8 (il-8)
WO2004045512A3 (fr) Anticorps monoclonaux humains contre cd25
WO2004043989A3 (fr) Anticorps monoclonaux humains diriges contre l'heparanase
MXPA05012571A (es) Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
RS20050724A (en) Human antibodies specific for interleukin 15(il-15)